Elsevier

Life Sciences

Volume 32, Issue 19, 9 May 1983, Pages 2247-2255
Life Sciences

Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline

https://doi.org/10.1016/0024-3205(83)90423-XGet rights and content

Abstract

N-ethoxycarbonyl−2-ethoxy−1,2-dihydroquinoline (EEDQ), an irreversible alpha adrenergic antagonist, also acts as a potent and longlasting in vivo antagonist of D-2 dopamine receptors. Rats given EEDQ 3−10 mg/kg i.p. exhibit catalepsy and greatly reduced apomorphine-induced stereotypy, behavioral effects associated with D-2 dopamine receptor blockade. These effects are apparent up to 4 days after drug administration, with scores returning to control level by day 7. In vitro receptor binding assays of striatal membrane preparations from these animals using the radioligand 3H-spiroperidol directly demonstrate that EEDQ is a potent D−2 dopamine receptor antagonist, revealing the apparent basis of the behavioral effects of EEDQ. This antagonism proceeds via a reduction in D-2 receptor Bmax, with no change in the observed KD for 3H-spiroperidol, and is resistant to extensive washing of the membrane preparation after in vivo EEDQ exposure. These observations suggest that EEDQ inhibition of D-2 receptors is irreversible. Administration of behaviorally active doses of EEDQ effect a reduction of 50−85% in D-2 receptor number. Recovery of this loss roughly parallels recovery of normal catalepsy and apomorphine stereotypy scores. These doses of EEDQ also reduce binding of 3H-flupentixol to D-1 and 3H-dopamine to D-3 type dopaminergic binding sites, putative dopamine receptors with no known behavioral correlates. Recovery of D-1 and D-3 binding also occurs with a similar timecourse. Because of the apparent covalent nature of its interaction with dopamine receptors and because of its activity after peripheral administration, EEDQ may prove useful in the study of the function and turnover of dopamine receptors.

References (22)

  • B. Belleau et al.

    Biochem. Pharm.

    (1969)
  • M.M. Bradford

    Anal. Biochem.

    (1976)
  • K.-J. Chang et al.

    Pharm. Res. Comm.

    (1970)
  • I. Creese et al.

    Brain Res.

    (1973)
  • M.W. Hamblin et al.

    Life Sci.

    (1982)
  • S. Kalsner

    Life Sci.

    (1970)
  • C.J.E. Niemegeers et al.

    Life Sci.

    (1979)
  • D.I. Schuster et al.

    Eur. J. Pharmacol.

    (1982)
  • B. Belleau et al.

    J. Am. Chem. Soc.

    (1968)
  • B. Belleau et al.

    J. Am. Chem. Soc.

    (1968)
  • B. Costall et al.

    Nature

    (1980)
  • Cited by (128)

    • Importance of D1 and D2 receptor stimulation for the induction and expression of cocaine-induced behavioral sensitization in preweanling rats

      2017, Behavioural Brain Research
      Citation Excerpt :

      These experiments employed a one-trial sensitization procedure in order to minimize the effects of tolerance and dependence, while permitting an unbiased measure of induction and expression [33]. In separate experiments, the irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), which has a high affinity for D1 and D2, 5-HT1A and 5-HT2A, α2-adrenergic, and GABAA receptors [36–42], was administered 24 h before the induction or expression of behavioral sensitization. To determine the relative involvement of DA receptors in these processes, selective DA antagonists were used to protect D1 and/or D2 receptors from EEDQ-induced receptor alkylation [43–46].

    • Potent haloperidol derivatives covalently binding to the dopamine D2 receptor

      2017, Bioorganic and Medicinal Chemistry
      Citation Excerpt :

      Due to the current absence of crystal structures of an antagonist-bound dopamine D2 receptor, substantial efforts have to be invested to learn more about the receptor-ligand interactions responsible for the stabilization of the receptor in its inactive state. To our knowledge, only a few covalent ligands have been reported to irreversibly antagonize the D2-receptors.30–32 In this work, we synthesized a set of covalent ligands derived from the classical antipsychotic drug haloperidol and the covalent dopamine analog FAUC150 irreversibly binding to a L94C cysteine mutant of the dopamine D2 receptor.7

    • Dopamine receptor inactivation in the caudate-putamen differentially affects the behavior of preweanling and adult rats

      2012, Neuroscience
      Citation Excerpt :

      The reason for this age-dependent difference has not been determined. In adult rats, EEDQ has been microinjected into various brain regions in order to examine whether D1 and/or D2 receptor stimulation contributes to the mediation of muscle tone, various unlearned behaviors, ipsilateral circling, and fixed-interval operant responding (Hamblin and Creese, 1983; Bordi et al., 1989; Cameron and Crocker, 1989; Giorgi and Biggio, 1990a,b; Lee et al., 1995; Neisewander et al., 1995; Hemsley et al., 2002; Cory-Slechta et al., 2002). For example, Neisewander et al. (1995) have shown that infusing EEDQ into the lateral CPu attenuates the SKF38393-induced grooming and oral movements of adult rats.

    • Biogenic amines in the nervous system of the cockroach, Periplaneta americana following envenomation by the jewel wasp, Ampulex compressa

      2012, Toxicon
      Citation Excerpt :

      It is therefore possible that Ampulex venom somehow interferes either with dopamine receptor function or the downstream signaling cascade resulting from receptor activation. Although there is scant information regarding dopamine receptor turnover in insects, it has been demonstrated previously that dopamine receptor turnover in rats takes around 7–10 days (Hamblin and Creese, 1983), similar to the time course of recovery from hypokinesia. These data suggest that even though dopamine levels are unchanged in stung animals, dopaminergic signaling overall may be compromised.

    View all citing articles on Scopus
    View full text